ChengDa Pharmaceuticals Co. Ltd. (301201) — Capital Reinvestment Ratio

Latest as of December 2025: 2.03x

ChengDa Pharmaceuticals Co. Ltd. (301201) has a Capital Reinvestment Ratio of 2.03x as of December 2025, meaning it reinvests 2% of its operating cash flow (CN¥34.02 Million) in capital expenditures (CN¥69.02 Million). Check ChengDa Pharmaceuticals Co. Ltd. (301201) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

2.03x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥34.02 Million
CNY

Capital Expenditures

CN¥69.02 Million
CNY

Data as of

Dec 2025
Most recent filing

ChengDa Pharmaceuticals Co. Ltd. Capital Reinvestment Ratio (2019–2025)

This chart tracks ChengDa Pharmaceuticals Co. Ltd.'s Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see 301201 cash generation efficiency.

Annual Capital Reinvestment Ratio for ChengDa Pharmaceuticals Co. Ltd. (2019–2025)

Year-by-year Capital Reinvestment Ratio for ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025. See 301201 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 2.03x CN¥34.02 Million CN¥69.02 Million ▼ -79.7%
2024 10.00x CN¥28.65 Million CN¥286.36 Million ▲ +754.6%
2023 1.17x CN¥192.07 Million CN¥224.67 Million ▼ -72.9%
2022 4.32x CN¥47.67 Million CN¥205.69 Million ▲ +158.7%
2021 1.67x CN¥83.14 Million CN¥138.70 Million ▲ +237.2%
2020 0.49x CN¥128.97 Million CN¥63.81 Million ▼ -34.6%
2019 0.76x CN¥67.52 Million CN¥51.06 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow